Interrupting Fibrosis: Targeting LPA and LPA1 in Pulmonary Fibrosis

In this APAPP podcast, Corinne Young, MSN, FNP-C, FCCP, is joined by Jessica Glennie, NP, of the Cleveland Clinic Interstitial Lung Disease Center, for a practical discussion on pulmonary fibrosis and the emerging LPA/LPA1 receptor pathway. The episode reviews the differences between idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), the clinical burden these conditions place on patients, and the biological processes that contribute to progressive lung scarring. Corinne and Jessica explore how fibroblast activation, collagen accumulation, inflammation, and LPA1 receptor signaling may contribute to fibrogenesis—and why targeting this pathway is generating interest in pulmonary fibrosis research. They also discuss how pulmonary advanced practice providers can monitor disease progression through symptoms, pulmonary function testing, oxygen saturation, and high-resolution CT imaging. Tune in for key clinical insights on early ILD detection, recognizing progression, monitoring patients every three to six months, and the future of targeted therapies for pulmonary fibrosis. Subscribe to the APAPP podcast and download the APAPP ACE app for more pulmonary education.